Skip to main content
Equibles

SIG BROKERAGE, LP

Broker-Dealer

Position in GALT — Galectin Therapeutics Inc

CIK 1094429 BALA CYNWYD, PA
Back to GALT Full portfolio

Position in GALT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$63,085
+$25,153 QoQ
Shares Held
13,596
0.0% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#66
of 98 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GALT Over Time

Shares Held

Position Value (USD)

Derivatives in GALT

reported options exposure · as of Dec 31, 2024
CallValue
$25,155
CallShares
19,500
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

SIG BROKERAGE, LP holds $14,503,065 across 7 Biotechnology names. GALT ranks #5 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 22,390 $11,121,784
2 DNTH
Dianthus Therapeutics, Inc. /DE/
 24,600 $2,398,008
3 RVMD
Revolution Medicines, Inc.
 2,846 $532,998
4 DFTX
Definium Therapeutics, Inc.
 6,563 $308,723
5 GALT
Galectin Therapeutics Inc
This page 		13,596 $63,085
6 NMRA
Neumora Therapeutics, Inc.
 27,483 $46,721
7 CMPX
Compass Therapeutics, Inc.
 14,496 $31,746

All Filings in GALT

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $63,085 13,596
2026-03-31 $37,932 13,596
2025-12-31 $56,559 13,596
2025-09-30 $66,640 15,717
2025-06-30 $41,145 19,500
2025-03-31 $23,790 19,500
2024-12-31 $25,155 19,500